Actelion's $250M deal for Ceptaris moves ahead; Ranbaxy may abandon smaller global markets;

@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma

@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce

@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story | Follow @CarlyHFierce

> Swiss-based Actelion ($ATLN) said its acquisition target Ceptaris won approval for its Valchlor gel drug in the U.S., clearing the way to wrap up the $250 million deal. Report

> India's Ranbaxy Laboratories may pull out of small markets around the world to focus on becoming a leader in selected key countries. Report

> Horizon Pharma and Par Pharmaceutical settled their patent fight over Duexis, which combines ibuprofen with the antacid drug Pepcid. Report

> Japan's Astellas Pharma launched a once-daily oral version of Astragraf, used to prevent organ rejection in kidney transplant patients. Report

> Indian antitrust officials will review 6 proposed pharma deals Tuesday amid calls for tighter restrictions on foreign investment in the sector. Report

> India's Lupin won FDA approval for its version of Sanofi's ($SNY) Rifampin, known generically as rifadin, a treatment for tuberculosis. Report

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev

@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce

@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce

@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce

> Medtronic fails to stop patient's Infuse lawsuit. News

> Investment bank launches healthcare-focused crowdfunding option. Item

Biotech News

@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech

@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. | Follow @JohnCFierce

@EmilyMFierce: High copper levels implicated in #Alzheimer's disease. Story | Follow @EmilyMFierce

> Argos turns to unusual players for $42.5M needed to fund PhIII cancer study. News

> AstraZeneca forges $500M cancer-combo tech buyout for MedImmune. More

> Amgen bags Onyx Pharma in $10.4B buyout deal. Story

CRO News

> U.K. outfit bets on early-phase outsourcing. News

> CRO Psi jumps into India. More

> Vince & Associates eyes gastro trials with expansion. Article

> Study: CROs dishing out bonuses to halt high turnover. Story

> Icon dives into adaptive trial monitoring. News

Biotech IT News

> Capgemini taps Amazon cloud for Big Data analytics. Story

> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article

> Google bolsters security of cloud data storage service. More

> FDA pilot project ups benefits of IT supply chain investments. News

> EMA to start accepting digital signatures next month. Story

And Finally... The American Academy of Pediatrics said breast-feeding mothers can take most prescription drugs without a risk to their babies' health. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.